QuidelOrtho Corporation’s Chief Legal Officer, Michelle A. Hodges, reported multiple equity transactions. On January 30, 2026, she received 38,562 restricted stock units (RSUs) and 38,561 non-qualified stock options with an exercise price of $27.17, with vesting scheduled between 2027 and 2029 and the options expiring in 2036.
On January 31, 2026, previously granted RSUs for 1,610 and 1,814 shares converted into the same number of common shares at no cost. The company withheld 578 and 651 shares at $27.17 per share to cover tax obligations. After these transactions, she directly held 39,555 shares of common stock.
QuidelOrtho Corporation reported an equity compensation grant to its Chief Financial Officer, Joseph M. Busky. On January 30, 2026, he was awarded 29,444 restricted stock units (RSUs), each representing one share of QuidelOrtho common stock, at a grant price of $0 as part of his compensation.
According to the vesting schedule, 9,814 shares will vest on January 30, 2027. The remaining 19,630 shares will vest in equal installments on January 30, 2028 and January 30, 2029, aligning Busky’s incentives with the company’s multi‑year performance.
QuidelOrtho Corporation President and CEO Brian J. Blaser received a grant of 213,470 restricted stock units on January 30, 2026. Each unit represents the right to receive one share of QuidelOrtho common stock.
According to the vesting schedule, 71,156 shares will vest on January 30, 2027. The remaining 142,314 shares will vest in equal installments on January 30, 2028 and January 30, 2029, aligning the CEO’s compensation with longer-term company performance.
QuidelOrtho Corporation executive Jonathan Philip Siegrist, EVP of R&D & CTO, reported equity compensation activity involving restricted stock units and common shares. On January 29, 2026, 2,448 restricted stock units vested and converted into the same number of QuidelOrtho common shares at $0 per share.
To cover tax withholding on this vesting, 1,009 common shares were disposed of at a price of $27.41 per share through share withholding. After these transactions, Siegrist directly owned 13,419 common shares and held 4,898 restricted stock units, which are scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.
QuidelOrtho Corporation’s Chief Operations Officer Philip D. McLellan reported routine equity compensation activity. On January 29, 2026, 4,897 restricted stock units vested and converted into an equal number of common shares at $0 per share. To cover tax withholding on this release, 2,017 common shares were withheld at $27.41 per share, leaving McLellan with 16,184 common shares held directly. After this vesting, he also holds 9,796 restricted stock units, scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.
QuidelOrtho Corp’s Chief Legal Officer, Michelle A. Hodges, reported equity award activity involving restricted stock units and common shares. On January 29, 2026, 7,836 restricted stock units converted into 7,836 shares of common stock at $0, reflecting the vesting of a prior award.
To cover tax withholding on this release, 3,072 common shares were withheld at a price of $27.41 per share. After these transactions, Hodges directly owned 37,360 shares of QuidelOrtho common stock and 15,673 restricted stock units, each representing the right to receive one share if and when it vests.
QuidelOrtho Corporation’s Chief Human Resources Officer, Ronald Lee Bowman, reported the vesting of 2,938 restricted stock units on January 29, 2026, which converted into the same number of common shares at $0 per share. Following this, 1,210 shares were surrendered at $27.41 per share to cover tax withholding obligations.
After these transactions, Bowman directly owned 3,375 shares of QuidelOrtho common stock. He also continued to hold 5,878 restricted stock units, which are scheduled to vest in equal installments on January 29, 2027 and January 29, 2028, each unit representing one share of common stock.
QuidelOrtho Corporation’s Chief Financial Officer Joseph M. Busky reported routine equity compensation activity. On January 29, 2026, 8,425 restricted stock units vested, converting into the same number of shares of common stock at $0 per share. To cover related tax withholding, 2,602 shares were withheld at $27.41 per share rather than sold in the open market.
After these transactions, Busky directly holds 37,250 shares of QuidelOrtho common stock and 16,851 restricted stock units. An additional 6,920 shares are held indirectly by a trust. The remaining RSUs are scheduled to vest in equal portions in 2027 and 2028.
QuidelOrtho Corp President and CEO Brian J. Blaser reported equity compensation activity tied to restricted stock units. On January 29, 2026, 21,446 restricted stock units vested, resulting in an acquisition of 21,446 shares of common stock at $0 per share.
To cover tax withholding on this vesting, 7,755 common shares were withheld by the issuer at $27.41 per share. After these transactions, Blaser directly beneficially owned 25,142 common shares and indirectly held 29,533 shares through a trust. The filing also notes 42,892 restricted stock units remain unvested, scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.
QuidelOrtho Corp (QDEL) director Kenneth J. Widder reported an option exercise and related share sale. On 11/25/2025, he exercised 7,021 non-qualified stock options at an exercise price of $15.74 per share, receiving the same number of common shares. On the same date, he sold 4,026 shares of common stock at a weighted average price of $27.8106 per share, with individual sale prices ranging from $27.81 to $27.83. Following these transactions, he directly beneficially owned 37,061 shares of QuidelOrtho common stock.